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ABSTRACT Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit
for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days
following the treatment. It is an innovative treatment whose clinical efficacy and safety are beginning to be
better understood. Since this is a device-based therapy, the overall evaluation of risk–benefit is unlike that of
pharmaceutical products; safety aspects, regulatory requirements, study design and effect size assessment
may be unfamiliar. The mechanisms of action and optimal patient selection need to be addressed in further
rigorous clinical and scientific studies. Bronchial thermoplasty fits in perfectly with the movement to
expand personalised medicine in the field of chronic airway disorders. This is a device-based complimentary
asthma treatment that must be supported and developed in order to meet the unmet needs of modern
severe asthma management. The mechanisms of action and the type of patients that benefit from bronchial
thermoplasty are the most important challenges for bronchial thermoplasty in the future.
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Introduction
Severe asthma continues to represent a challenge for physicians. New treatment strategies and approaches
are urgently needed for these patients [1]. Appropriate patient selection is paramount when considering
any new treatment modality, be it pharmacological or device based. Bronchial thermoplasty is a
nonpharmacological, device-based therapy that delivers controlled thermal energy to the airway wall as part
of a series of three bronchoscopic procedures. It was approved by the US Food and Drug Administration for
the treatment of severe persistent asthma in patients aged o18 years whose asthma is not well controlled
with inhaled corticosteroids (ICS) and long-acting b2-agonists (LABAs) in 2010, and was CE marked and
available in Europe since 2011. The clinical development programme consisted of five clinical trials; four
were in subjects with asthma and three were randomised. The largest sham-controlled device-based clinical
trial in severe asthma, the Asthma Intervention Research (AIR)2 Trial, has recently published 5-year efficacy
and safety data [2]. Despite the large body of clinical work, many unresolved questions remain [3]. This
review will summarise the information on mechanism of action, procedure, efficacy, safety and patient
selection, to better understand the path forward for this promising technique.
How do we perform bronchial thermoplasty?
Bronchial thermoplasty is an interventional bronchoscopic procedure for the treatment of severe,
uncontrolled asthma patients. Although simple in principle, correct procedure execution requires accurate
and meticulous identification of airway anatomy via bronchoscopy. It should only be performed by an
experienced bronchoscopist in a healthcare setting with appropriate clinical monitoring and the ability to
address any potential post-intervention complications. The appropriate assessment and monitoring of the
patient before, during and after the procedure has been described by MAYSE et al. [4].
Bronchial thermoplasty must only be offered to patients with documented asthma. At present, warnings,
precautions and exclusions include chronic obstructive pulmonary disease, bronchiectasis, recurrent
respiratory infections or any other uncontrolled significant respiratory disease. The treating facility (asthma
specialist and interventional bronchoscopist) should be familiar with the patient and his/her clinical course
in order to ensure appropriate patient selection and optimal asthma control prior to bronchial thermoplasty
and during the entire treatment period. Treatment with bronchial thermoplasty can, in fact, lead to
temporary worsening of asthma symptoms, the intensity of which may be proportional to the severity of the
patient’s asthma [5–7]. Peri-procedure systemic corticosteroid therapy, admission to hospital for intensive
respiratory monitoring and/or bronchoscopy may be necessary. At the end of the treatment period (6 weeks
after the final bronchoscopy), the clinical benefit should ideally be reassessed. Pharmacological treatments
should be adjusted to their lowest possible dosages, starting with a reduction of oral corticosteroids (OCS)
and followed by a reduction in ICS and/or LABA if the asthma remains well controlled [8]. There are no
data on the effects of bronchial thermoplasty on airway inflammation to empirically guide pharmacological
treatment, nor are there data on the effects of medication withdrawal following bronchial thermoplasty in a
forced medication withdrawal study design other than a small safety study in very severe asthma patients [5].
The procedure in practice
Performing bronchial thermoplasty requires bronchoscopic rigour, dexterity and a thorough knowledge of
the airway anatomy. Three treatment sessions at approximately 3-week intervals are recommended; full
recovery of the patient between treatments is necessary in order to proceed. The sequence of treatments
involves the right lower lobe (first session) then left lower lobe (second session), followed by both upper
lobes (third session). The right middle lobe is not treated, as the clinical programme excluded this area
based on the theoretical possibility of obstruction and right middle lobe syndrome. Each bronchial
thermoplasty session takes ,30–45 min. Each bronchus is treated along its entire visible length, with each
activation targeting a 5-mm section of bronchus between 3 and 10 mm in diameter, beginning at the
periphery and moving proximally. Areas should not be retreated. A full treatment consists of ,30–70
activations per lobe (depending on the specific anatomy); on average, 44 for the right lower lobe, 47 for the
left lower lobe and 60 for the upper lobes are performed [9]. The effectiveness of the treatment may depend
on how thoroughly the procedure is performed; if a segment is left untreated it may theoretically continue
to constrict when stimulated, potentially negating the benefits of the treatment. This is why meticulous
technique and airway mapping is so important. Activation of the bronchial thermoplasty catheter (fig. 1)
does not produce any macroscopic effect on the bronchial mucosa but may result in transient blanching
represented by a whitening of the mucosa. This makes it difficult to identify the treated bronchi and
requires close attention on the part of the bronchoscopist in order to know which segments have been
treated. As a result, in contrast to other procedures (such as laser treatment of an obstructive lesion, ablation
of a mucous blockage or foreign body, etc.), there is no visible indication of treatment. Close clinical
monitoring is required immediately following the procedure, as asthma symptoms are more common in the
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hours immediately following treatment. Bronchial thermoplasty requires great patience if there are
abundant secretions or uncontrollable cough, when the airways move on inspiration (especially in the lower
lobes) or if the bronchial mucosa is friable. The procedure can be carried out under sedation or general
anaesthesia, depending on resources and physician/institution preference. Some patients report an
improvement in their asthma after the first treatment. Although carrying out bronchial thermoplasty
may seem straightforward, this treatment requires expertise in asthma management and interventional
bronchoscopy. In addition, a multidisciplinary team combining physicians with a specific interest in
interventional endoscopy and those with an expertise in chronic airway disorders will ensure the best
possible care to the most appropriate patient.
Is it efficacious?
After an initial study exploring the safety and clinical effects of bronchial thermoplasty in patients with mild
to moderate asthma [9], three randomised clinical trials were carried out in patients with moderate to
severe asthma [5–7]. The AIR Trial was a randomised, controlled study in 112 asthma patients (56 received
bronchial thermoplasty and 56 received standard-of-care) who required treatment with ICS and LABA. The
principal outcome measure was the average frequency of mild exacerbations during the LABA withdrawal
periods. The Research in Severe Asthma (RISA) Trial was a randomised, controlled safety study in 32 severe
patients whose asthma was uncontrolled despite high-dose ICS (15 patients received bronchial thermoplasty
and 17 continued with usual care) [5]. After the initial evaluation, there was forced steroid withdrawal to
attempt to wean patients from ICS and OCS between weeks 22 and 36. The largest study, AIR2 [7], was a
double-blinded, randomised, sham-controlled study that enrolled patients who had uncontrolled asthma
a)
c) d)
b)
Thermoplasty
procedure
FIGURE 1 Bronchial thermoplasty procedure. a) Bronchial thermoplasty is performed through fibreoptic bronchoscopy. b) A catheter is inserted in a proximal
bronchus. c) The catheter is opened in situ. d) The catheter delivers controlled thermal energy.
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despite high-dose ICS and a LABA. 190 patients were treated with bronchial thermoplasty and 98 received
sham thermoplasty. The sham thermoplasty treatment reproduced all the audio and visual signals of the
technique but the catheter did not deliver any radiofrequency energy. The treatment was administered by an
unblinded bronchoscopy team and all the assessments and follow-up visits were conducted by a blinded
team. The primary outcome measure was change from baseline in average group mean Asthma Quality of
Life Questionnaire (AQLQ) score. Details of these trials are summarised in tables 1 and 2.
Effects on quality of life
In the AIR study, AQLQ improved significantly in comparison with the control group [6]. In the RISA
study, although bronchial thermoplasty-treated subjects were on reduced maintenance therapy following
the steroid wean phase, they showed an improvement in their quality of life compared with control subjects
[5]. In AIR2, compared with sham control, the bronchial thermoplasty-treated group demonstrated
superior AQLQ scores as well as a greater proportion with a clinically meaningful improvement in AQLQ
(o0.5) in the intent-to-treat and per-protocol groups (79% versus 64% and 81% versus 63%; posterior
probability of superiority (PPS) 99.6% and 99.9%, respectively) [7].
Effects on asthma control
In the initial feasibility study, COX et al. [9] reported an improvement in the number of symptom-free days
in the 3 months following bronchial thermoplasty. In AIR, asthma control improved after bronchial
thermoplasty; subjects had more symptom-free days and a significant improvement in quality of life [6].
Furthermore, the bronchial thermoplasty-treated subjects used less rescue medication, equating to
TABLE 1 Inclusion criteria in studies into bronchial thermoplasty
Feasibility study [9] AIR study [6] RISA study [5] AIR2 study [7]
Age years o18 18–65 18–65 18–65
ICS dose# mg f1500 or 200–1800" o200 .1500 .1000
LABA dose mg 0–100 o100 o100 o100
OCS dose mg?day-1 0 0 f30 f10
Pre-BD FEV1 % predicted 60–85 60–85 o50 o60
AIR: Asthma Intervention Research; RISA: Research in Severe Asthma; ICS: inhaled corticosteroids; LABA: long-acting b2-agonist; OCS: oral
corticosteroids; BD: bronchodilator; FEV1: forced expiratory volume in 1 s. #: beclomethasone dipropionate equivalent; ": inclusion criteria
different at the two participating sites (Narinder Shargill, Boston Scientific, San Jose, CA, USA; personal communication).
TABLE 2 Main characteristics of studies into severe asthma
Study Features Duration
weeks
Assessments Inclusion criteria Subjects n Control
RISA [5] Multicentre,
randomised,
parallel groups
52 Changes: ICS, OCS, PEFR, FEV1,
AQLQ, safety
Age 18–65 years, ICS
.750 mg, FP+LABA,
pre-BD FEV1 o50%
pred, uncontrolled
32 Continue usual
ICS+LABA
AIR [6] Multicentre,
randomised,
parallel groups
52 Changes: ICS, OCS, rescue b2
agonists, exacerbations, PEFR,
FEV1, AQLQ, safety during LABA
withdrawal periods
Age 18–65 years, ICS
o200 mg, BDP+LABA,
pre-BD FEV1 60–85%
pred
109 Continue usual
ICS+LABA
AIR2 [7] Multicentre,
randomised,
placebo,
double-blind,
parallel groups
52 Number of asthma-free days,
exacerbations (admissions,
urgent care), rescue b2 agonists,
PEFR, FEV1, AQLQ, absenteeism,
safety
Age 18–65 years, ICS
.1000 mg,
BDP+LABA, pre-BD
FEV1 o60% pred
288 Three sham sessions of
bronchial thermoplasty
every 3 weeks,
continue usual
ICS+LABA
RISA: Research in Severe Asthma; AIR: Asthma Intervention Research; ICS: inhaled corticosteroids; OCS: oral corticosteroids; PEFR: peak
expiratory flow rate; FEV1: forced expiratory volume in 1 s; AQLQ: Asthma Quality of Life Questionnaire; FP: fluticasone propionate; LABA: long-
acting b2-agonist; BD: bronchodilator; BDP: beclomethasone dipropionate. For all three studies, thermoplasty treatment consisted of three
sessions of bronchial thermoplasty every 3 weeks, while continuing usual ICS+LABA.
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approximately two fewer canisters of short-acting bronchodilators per year. In RISA, the bronchial
thermoplasty-treated group demonstrated improved asthma control and reduced use of rescue medications
prior to the forced steroid withdrawal period [5]. Despite a reduction in medication following the steroid
wean phase, the bronchial thermoplasty-treated group continued to show reduced use of short-acting
bronchodilators, more symptom-free days and maintenance of an improved Asthma Control Questionnaire
(ACQ) score. AIR2 saw a significant reduction in the number of bronchial thermoplasty-treated subjects
with worsening asthma compared with sham in the post-treatment period (27.3% versus 42.9%,
respectively; PPS 99.7%) [7]. There was no difference in the number of symptom-free days, use of rescue
medications or the total asthma symptom score.
Effects on asthma exacerbations, use of urgent care and absences from work or school
In AIR, the bronchial thermoplasty-treated group presented, on average, fewer mild exacerbations during the
LABA withdrawal period at 1 year than the control group [6]. In AIR2, compared with sham control, the
bronchial thermoplasty-treated group demonstrated superiority, with fewer severe exacerbations (-32%; PPS
95.5%), visits to urgent care (-84%; PPS 99.9%) and days absent from work or school (-66%; PPS 99.3%) [7].
Effects on lung function and airway responsiveness
The feasibility study reported improvements in expiratory flow and airway responsiveness 3 and 12 months
after bronchial thermoplasty [9]. These improvements persisted for up to 3 years, although this finding was
not significant due to the high number of patients lost to follow-up, especially in the untreated group. In AIR,
morning peak flow measurements were better than in the control group [6]. In AIR2, no change in respiratory
function was noted at 1 year post treatment, but there was a reduction in steroid consumption [7]. In fact, the
effects of bronchial thermoplasty on asthma were comparable to those of omalizumab, with improvements in
exacerbation rate and quality of life but little or no effect on respiratory function [10].
Sparing effect on corticosteroid therapy
In RISA, the use of OCS and ICS fell by 63.5% and 28.6%, respectively, in bronchial thermoplasty-treated
subjects, compared with 26.2% and 20% in the control group. In spite of reduced maintenance therapy,
significant improvements were seen in quality of life and asthma symptom scores 4 months after the steroid
wean phase [5].
Effects on lung morphology assessed by imaging
Airway imaging is a minimally invasive modality for assessing the efficacy and safety of bronchial
thermoplasty. A study using computed tomography (CT) in canine models has been carried out by BROWN
et al. [11]. Some authors have looked at the effects of bronchial thermoplasty on bronchial calibre, bronchial
sensitivity to methacholine and response to deep inspiration [12]. Measurements at 5 weeks after treatment
suggested reduced airway hyperresponsiveness with no change in lung compliance. In the feasibility study, 16
subjects were assessed by high-resolution CT (HRCT) at baseline, 1 year and 2 years; there was no consistent
evidence for bronchiectasis, bronchial wall thickening or other structural abnormalities of the bronchi or
parenchyma [9]. The results at 5 years in the 93 AIR2 subjects for whom initial and post-treatment HRCT
imaging was available showed either no change or improvement in 82% of cases. Worsening or newly
developed bronchiectasis was reported in only three (3%) patients [7]. There is no mention of the mosaic
pattern that can point to constrictive bronchiolitis, bronchial stenosis or emphysema [2].
Data on the effects of bronchial thermoplasty are still quite limited; two of the randomised clinical trials
were not blinded. Furthermore, these results are difficult to generalise to the real-life severe asthma
population, as many will have characteristics outside of the clinical study eligibility criteria. Overall,
bronchial thermoplasty demonstrated improved quality of life but there was a large sham effect, a common
finding in studies exploring quality of life in severe asthma [10]. The beneficial effects of bronchial
thermoplasty on quality of life and asthma control as well as a reduction in doses of ICS or OCS in
randomised trials are consistent. Bronchial thermoplasty treatment also appears to lead to a decrease in
airway hyperresponsiveness without any changes in respiratory function. A recent analysis showed that the
beneficial effects of bronchial thermoplasty seem to last for at least 5 years [2, 13, 14]; however, studies over
a longer term are needed.
What is the safety profile?
Adverse events observed during the treatment phase (up to 6 weeks after the final bronchoscopy) and the
post-treatment phase (from 6 weeks after the final bronchoscopy) have been described for each of the four
clinical trials (table 3): the feasibility study in mild to moderate asthma, AIR in moderate to severe asthma [6],
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AIR2 in moderate to severe asthma [7] and RISA in severe asthma patients. In three of the studies, longer-term
adverse events up to 5 years have been described [2, 14, 15].
Adverse events in the initial treatment period
Bronchial thermoplasty-treated subjects presented with more symptoms typical of asthma (e.g. cough,
wheeze, expectoration, dyspnoea, nocturnal awakening) than control subjects, and occasionally had general
symptoms such as fever in the hours following treatment. These symptoms usually resolved after 7 days but
led to hospital admission in 3.4% of bronchoscopies in moderate to severe asthma in AIR2 and 15.6% of
severe asthma cases in RISA (table 3). This finding underlines the importance of optimising asthma control
prior to the first bronchial thermoplasty treatment and ensuring close monitoring in the days following
treatment. In AIR2, one patient presented significant haemoptysis from the right upper lobe 1 month after
the last session and required bronchial artery embolisation. Slight bleeding had been observed during the
treatment of this lobe and this complication was considered to be probably related to the treatment [7].
Adverse events at 1 year and in the longer term
Asthma is associated with structural and inflammatory changes of the bronchial mucosa [16], and the
application of controlled thermal energy (65uC) raises the question of whether bronchial thermoplasty may
induce further injury to the bronchial wall. After long-term follow-up in the four clinical trials, there was no
evidence for treatment-related airway stenosis or bronchiectasis. None of the trials documented any
bronchial damage at 1 year of follow-up. One case of pulmonary abscess developed 14 months after
treatment in AIR2 [13]. The affected upper left lobe underwent surgical resection and no bronchial
abnormality was documented on histological examination. The abscess was considered to be secondary to a
respiratory infection with no clear connection to bronchial thermoplasty.
During this 5-year follow-up, pre-bronchodilator forced expiratory volume in 1 s (FEV1) remained stable in
the two studies of patients with moderate to severe asthma [2, 14]. Additionally, chest radiography [13] and
HRCT at 3 and 5 years did not show any significant structural changes other than transient and temporary
abnormalities typically seen in moderate to severe asthma [2]. In RISA, follow-up of chest radiographs at
5 years was performed in the small group with the most severe asthma; no significant changes were
documented, FEV1 did not deteriorate, and the number of hospital admissions for exacerbation of asthma
had fallen over this period [14].
Who is a candidate for bronchial thermoplasty?
Clinical studies of bronchial thermoplasty in adults with asthma have addressed a broad range of asthma
patient severity, from mild to severe. Although it is true that most patients presented with inadequate
control of their asthma and most had evidence of airways obstruction, maintenance asthma treatments and
ICS doses were variable. Moreover, some patients received OCS as well [5]. Bronchial thermoplasty has
been administered in clinical trials in difficult (uncontrolled) cases of asthma but not exclusively in those at
the extreme end of the severity spectrum (table 3).
ICS dose
There may be a tendency to reserve bronchial thermoplasty for patients whose asthma is uncontrolled
despite the combination of high-dose ICS and LABA. The required daily dose of ICS prior to considering
bronchial thermoplasty is not entirely clear; benefits were seen in uncontrolled subjects despite a daily dose
of fluticasone .750 mg in RISA [5], beclomethasone .1000 mg in AIR2 [7], and moderate doses of ICS
in other studies [9]. We recommend that medical treatment be optimised before offering bronchial
thermoplasty.
Lung function
In the clinical development programme, FEV1 had been considered when assessing subjects for eligibility.
This was justified by the increased incidence of hospitalisation following bronchoscopy for bronchial
thermoplasty in subjects whose asthma is very severe (15.6% in RISA versus 3.4% in AIR2). The AIR2 study
required a pre-bronchodilator FEV1 of .60% of predicted versus at least 50% of predicted in RISA
for eligibility.
Airways hyperresponsiveness
The clinical programme included patients that were selected at least in part due to evidence for bronchial
hyperreactivity expressed as either a significant response to b2 agonists, deterioration on withdrawal of b2
agonists or increased responsiveness to methacholine. For example, eligibility criteria in AIR included a
bronchodilator response of 12% after 400 mg of inhaled salbutamol or a positive methacholine challenge
ASTHMA | M-C. DOMBRET ET AL.
DOI: 10.1183/09059180.00005114 515
T
A
B
L
E
3
R
e
sp
ir
a
to
ry
si
d
e
-e
ff
e
ct
s
d
u
ri
n
g
b
ro
n
ch
ia
l
th
e
rm
o
p
la
st
y
tr
e
a
tm
e
n
ts
in
se
ve
re
a
st
h
m
a
S
tu
d
y
g
ro
u
p
A
st
h
m
a
se
ve
ri
ty
S
u
b
je
ct
s
B
ro
n
ch
o
sc
o
p
ie
s
S
ym
p
to
m
s#
S
ym
p
to
m
s#
p
e
r
b
ro
n
ch
o
sc
o
p
y
M
il
d
%
M
o
d
e
ra
te
%
S
e
ve
re
%
H
o
sp
it
a
l
a
d
m
is
si
o
n
s"
(s
u
b
je
ct
s)
H
o
sp
it
a
l
a
d
m
is
si
o
n
s"
p
e
r
b
ro
n
ch
o
sc
o
p
y
F
e
a
si
b
il
it
y
st
u
d
y
M
il
d
to
m
o
d
e
ra
te
1
6
4
9
1
5
5
3
.2
8
4
1
6
0
0
0
A
IR
M
o
d
e
ra
te
to
se
ve
re
5
5
1
6
1
4
0
7
2
.5
6
9
2
8
3
6
(4
)
0
.0
4
A
IR
2
:
th
e
rm
o
p
la
st
y
g
ro
u
p
M
o
d
e
ra
te
to
se
ve
re
1
9
0
5
5
8
5
7
3
1
.0
4
4
5
3
3
.1
1
9
(1
6
)
0
.0
3
4
A
IR
2
:
sh
a
m
g
ro
u
p
M
o
d
e
ra
te
to
se
ve
re
9
8
2
9
2
2
0
6
0
.7
5
5
4
0
1
.5
2
(2
)
0
.0
0
7
R
IS
A
S
e
ve
re
1
5
4
5
1
3
6
3
.0
4
9
4
1
1
0
7
(4
)
0
.1
5
6
D
a
ta
a
re
p
re
se
n
te
d
a
s
n
,
u
n
le
ss
o
th
e
rw
is
e
st
a
te
d
.
A
IR
:
A
st
h
m
a
In
te
rv
e
n
ti
o
n
R
e
se
a
rc
h
;
R
IS
A
:
R
e
se
a
rc
h
in
S
e
ve
re
A
st
h
m
a
.
#
:
re
sp
ir
a
to
ry
-r
e
la
te
d
a
d
ve
rs
e
e
ve
n
ts
d
u
ri
n
g
th
e
tr
e
a
tm
e
n
t
p
e
ri
o
d
(f
ro
m
fi
rs
t
b
ro
n
ch
o
sc
o
p
y
to
6
w
e
e
k
s
a
ft
e
r
th
e
fi
n
a
l
b
ro
n
ch
o
sc
o
p
y)
;
"
:
d
u
ri
n
g
th
e
tr
e
a
tm
e
n
t
p
e
ri
o
d
.
ASTHMA | M-C. DOMBRET ET AL.
DOI: 10.1183/09059180.00005114516
test defined as ,8 mg?mL-1 [6]. In addition, in patients who were already treated with a combination of
ICS and LABA, a significant functional or uncontrolled deterioration in the 2 weeks after stopping the
LABA was required as well. In the real world, measuring bronchial hyperresponsiveness using a challenge
test prior to bronchial thermoplasty may be problematic in severe asthma, especially when baseline
respiratory function is compromised.
Absence of asthma control
Bronchial thermoplasty is indicated in cases of asthma that are inadequately controlled or uncontrolled
despite maximal medical therapy; this defines difficult asthma. Asthma control can be assessed in various
ways, including by frequency of exacerbations and by composite questionnaires such as the Asthma Control
Test and ACQ (based on recent daily symptoms) [17]. The effects of bronchial thermoplasty on reduction
in exacerbations were very clearly shown in AIR2 during the post-treatment period [7]; however, it may not
be essential to have a history of severe exacerbations to benefit from bronchial thermoplasty. Asthma that
remains uncontrolled despite maximal medical therapy is consistent with the patient population studied in
the clinical programme.
Contraindications
Patients with a history of life-threatening asthma were excluded from the clinical programme. Similarly,
both three or more hospital admissions or four or more courses of systemic corticosteroids in the year
preceding bronchial thermoplasty were exclusion criteria in AIR2 [13]. Heavy use of short-acting
bronchodilators (.4 puffs?day-1) was also an exclusion criterion for AIR2. The procedure poses a
theoretical risk of infection. It seems reasonable to exclude patients with a history of three or more proven
respiratory infections treated with antibiotics in the previous year [6]. Because of the theoretical risk of
infection, bronchiectasis is at present an absolute contraindication to bronchial thermoplasty. Chronic
rhinosinusitis was a contraindication for the AIR and AIR2 studies, presumably because of the difficulties
distinguishing clinical events associated with rhinosinusitis from asthma [7]. Subjects with a smoking
history of .10 pack-years were excluded from the clinical programme; no information on the safety or
effectiveness of bronchial thermoplasty in this patient population is available.
Responsive phenotypes
We might imagine that the patients who benefit the most from bronchial thermoplasty would be those who
have greater airway hyperreactivity as demonstrated by response to b2 agonists, response to methacholine
challenge or tendency to frequent exacerbations. In the same way, we might think that bronchial
thermoplasty would be even more effective in those where smooth muscle contraction plays an important
role in their disease; however, there are no clinical data to support this assumption. Similarly, there is little
evidence that the inflammatory phenotype is relevant to clinical response. Even if we believe that airway
hyperresponsiveness is an important criterion for response to bronchial thermoplasty, there is only a weak
relationship between eosinophilic inflammation and airway hyperresponsiveness to direct stimuli [18].
Likewise, the presence or absence of allergies by self-report or other predisposing factors does not seem to
be a factor that can predict response to bronchial thermoplasty [2].
How does it work?
Bronchial thermoplasty is a procedure that delivers controlled thermal energy at 65uC to airways between 3
and 10 mm diameter via a bronchoscope under direct visual guidance (fig. 1). There are a number of
possible mechanisms of action that alone, or in combination, might explain the beneficial effects of
bronchial thermoplasty. To date, no unique mechanism has been formally identified.
Because an increase in airway smooth muscle (ASM) mass is one of the major characteristics of airway
remodelling in severe asthma patients [16], the first and most well documented mechanism of action
concerns reduction in the bronchial wall smooth muscle [19]. A number of reports have emphasised the
effects of increased smooth muscle mass in severe asthma, particularly on airway hyperresponsiveness and
permanent airflow limitation [20, 21]. A reduction in ASM mass after bronchial thermoplasty has been
observed experimentally in a canine model [11] and in nonasthmatic human lobectomy specimens
examined between 1 and 3 weeks after bronchial thermoplasty [22]. This reduction in ASM was directly
linked in dogs to a decrease in airway hyperresponsiveness; however, reduction in airway hyperrespon-
siveness in asthmatic human subjects after bronchial thermoplasty was inconsistent [13].
A second mechanism might involve a direct effect on the contractile properties of the ASM or a stiffening
of the bronchial wall to which the smooth muscle attaches. The effects of the application of var-
ious temperatures on in vitro contraction of bovine bronchial smooth muscle have been examined.
Acetylcholine-induced contraction of bronchial smooth muscle was inhibited at temperatures exceeding 55uC,
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while relaxation mediated by a b2 agonist was not affected, suggesting that bronchial thermoplasty may alter
the contractile properties of ASM cells [23]. Interactions between actin and myosin were also very sensitive to
temperature, and changes occurred in the absence of any histological signs of necrosis or apoptosis. It is
unclear whether the acute phenomena observed in vitro may persist in the long term in vivo and whether they
may be the cause of reduced airway contractility.
Other potential mechanisms of action include decreased secretion of inflammatory mediators by ASM cells
and changes to the epithelium of the airways, the nerve endings or the function of the inflammatory cells
that infiltrate the bronchial mucosa.
Currently, the mechanisms of action for bronchial thermoplasty are poorly understood. Aside from the
issue of reduced ASM mass, many questions remain (see online supplementary material for a list). None of
the potential mechanisms mentioned have been studied either in preclinical experimental models of asthma
or in clinical studies, and more work is needed in order to elucidate the various potential mechanisms of
action of bronchial thermoplasty. Ultimately, this understanding may allow for improved appropriate
patient selection.
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